본문 바로가기 주메뉴 바로가기
22대 대한민국 국회 국회정보길라잡이 국회의원검색
회원가입 로그인
HOME

정보검색

소장정보 검색

국회도서관 홈으로 정보검색 소장정보 검색

결과 내 검색

동의어 포함

고급검색

인명/단체명

저자정보 상세정보
인명/단체명을 입력하세요.

키워드

  • 대표어

  • 외국어

-

초록보기

Objectives: This was to evaluate the current usage of three erythropoietin stimulating agents (ESA) and their efficacy for management of anemia in peritoneal dialysis (PD) patients with chronic kidney disease.

Methods: It was a retrospective comparative study through review of electronic medical records of chronic kidney disease patients undergoing PD at a tertiary teaching hospital from January 1998 to June 2013.

Results: Average administration frequency was 1.66 times/week in EPO group, 0.75 times/week in DA group, and 0.19 times/week in MPG-EPO group. At the first 4 weeks, there were significant differences in mean hemoglobin levels between EPO and DA groups (9.25±1.28 g/dL, 10.02±0.95 g/dL each, p = 0.018) and also in hemoglobin response rates (10.0%, 45.2% each, p = 0.008), but since after 4 week, there had been no significant differences. There also showed no significant differences in achievement of hemoglobin target between the two groups. When converted to MPG-EPO in EPO/DA groups, there showed a slight increase in hemoglobin levels of both groups. MPG-EPO was the highest compared with two other drugs by the average cost based on the average weekly dose.

Conclusion: EPO, DA, and MPG-EPO showed similar effects in treatment of anemia of PD patients based on hemoglobin target range (11.0~12.0 g/dL) which NFK-K/DOQI guidelines suggest. Though the average cost of MPG-EPO was higher than the other two drugs, the number of PD patients using MPGEPO has increased and it is thought that long half-life and low administration frequency of MPG-EPO have improved the compliance of PD patients who have to self-administrate.

권호기사

권호기사 목록 테이블로 기사명, 저자명, 페이지, 원문, 기사목차 순으로 되어있습니다.
기사명 저자명 페이지 원문 목차
제2형 당뇨병 환자에서 시타글립틴과 메트포민 고정 복합제 투여와 단일제 병용간의 복약 순응도, 효과 및 약가에 대한 비교 연구 박지혜, 곽혜선, 이병구, 김재연 pp.193-198

Historical Transition and Future Task of Pharmacist License Examination in Korea. 2 한국약학교육협의회 의약품품질과학분과회, 유봉규 pp.230-230
임상약학, 임상약사, 임상약료와 임상약과학에 대한 인식도 조사 연구 장민정, 이장익, 조은애, 노하연 pp.169-182

만성신부전 환자의 혈관 석회화와 사망률에 미치는 인결합제의 영향 신혜연 pp.199-205

파스제의 점착력 관리기준 및 피부 부작용 조사연구 김지연, 이원재, 김광준, 박상욱, 방준석 pp.219-228

일반의약품 약국 외 판매 이후의 일반의약품 정책에 대한 소비자의 인식 변화 김은희, 방준석 pp.183-192

복막투석 환자의 빈혈 관리에 있어 에리스로포이에틴 자극제의 사용현황 및 비교평가 임수연, 이정연, 진혜경, 김선아, 이은경 pp.206-212

임상 자료를 활용한 레보세티리진과 세티리진이 유도한 간손상 평가 성은지, 이주연, 문미라, 조윤숙, 이혜숙, 김향숙 pp.213-218

Historical Transition and Future Task of Pharmacist License Examination in Korea. 1 한국약학교육협의회, 유봉규 pp.229-229

참고문헌 (27건) : 자료제공( 네이버학술정보 )

참고문헌 목록에 대한 테이블로 번호, 참고문헌, 국회도서관 소장유무로 구성되어 있습니다.
번호 참고문헌 국회도서관 소장유무
1 Current status of dialysis therapy for ESRD patients in Korea 소장
2 Current status and future in patients with end stage renal disease in Korea 네이버 미소장
3 Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States 네이버 미소장
4 Methoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease. 네이버 미소장
5 Ahn SC., Choi SO., Shin SJ. (1994), Anemia in patients with chronic renal failure on hemodialysis. Kidney Res Clin Pract, 13(4),769-75. 미소장
6 KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. 네이버 미소장
7 Pharmacokinetics and application of erythropoietin therapy: overview of epoetin alfa studies in Japan. 네이버 미소장
8 Horl WH. (2013), Differentiating factors between erythropoiesis stimulating agents: an update to selection for anaemia of chronic kidney disease. Drugs, 73(2),117-30. 미소장
9 An extended terminal half-life for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis. 네이버 미소장
10 Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. 네이버 미소장
11 C.E.R.A.: pharmacodynamics, pharmacokinetics and efficacy in patients with chronic kidney disease. 네이버 미소장
12 Methoxy polyethylene glycol-epoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease. 네이버 미소장
13 Dougherty FC., Reigner B., Jordan P. (2004), Continuous erythropoiesis receptor activator (CERA) provides dosedependent erythropoietic activity with a prolonged half-life in healthy volunteers. Ann Oncol, 15(suppl 3), iii157 (Abstr 2943). 미소장
14 Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. 네이버 미소장
15 KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD 네이버 미소장
16 Factors influencing erythropoietin compliance in peritoneal dialysis patients 네이버 미소장
17 Lee JY., Byun SW., Yeo YS. (2009), Comparison of erythropoietic effect between epoetin-α and darbepoetin-á in hemodialysis patients: A randomized crossover study. Kidney Res Clin Pract, 28(5),450-5. 미소장
18 Yoo SH., Kang JM., Kang GW. (2000), Phase III clinical study of recombinant human erythropoietin (Eporon®) on anemia of chronic renal failure. Kidney Res Clin Pract, 19(6),1053- 62. 미소장
19 Product Information: MIRCERA(R) injection, methoxy polyethylene glycol-eopetin beta injection. Hoffmann-La Roche,Inc, Nutley, NJ, 2007. 미소장
20 Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients 네이버 미소장
21 Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients 네이버 미소장
22 Shin SH., Lee YS. (2011), Determinants of erythropoietin hyporesponsiveness in management of anemia in hemodialysis patients. Kor J Clin Pharm, 21(2),122-30. 미소장
23 A Randomized Trial of Depression Assessment Intervention in Home Health Care 네이버 미소장
24 Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. 네이버 미소장
25 Park SK., Hwang KS., Park JS. (2011), Hemoglobin variability associated with different erythropoiesis stimulating agents in hemodialysis patients. Kidney Res Clin Pract, 30(1),41-7. 미소장
26 Cost Analytic Model to Determine the Least Costly Inpatient Erythropoiesis Stimulating Therapy Regimen 네이버 미소장
27 Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients 네이버 미소장

추천서가 (다양한 추천 자료를 만나보세요)

권호기사보기

권호기사 목록 테이블로 기사명, 저자명, 페이지, 원문, 기사목차 순으로 되어있습니다.
기사명 저자명 페이지 원문 기사목차

권호

기사명 원문보기 기사목차
닫기